Achillion Pharma (ACHN) Reports Q3 Loss of $0.15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Achillion Pharma (ACHN) Reports Q3 Loss of $0.15

Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs

November 3, 2016 9:01 AM EDT

Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillions phase I MAD study with oral factor D inhibitor ACH-4471 ongoing; strong complement inhibition observed in in vivo and ex vivo assays Company advancing small molecule candidates for the treatment of dry AMD

NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today reported financial results for the three months ended September 30, 2016. For the... More